MT Newswires Live10:46
Sichuan Biokin Pharmaceutical (SHA:688506) received approval from China's National Medical Products Administration for the clinical trial for its BL-M12D1 injection, according to a Shanghai bourse filing on Monday.
The drug will be tested as a monotherapy for relapsed or refractory hematological malignancies, or a group of cancers affecting the blood, bone marrow and lympatic system.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
